Antibody-targeting of SDC1 has been used alone or combined with chemotherapy to treat multiple myeloma [231], and a clinical trial using CAR-T cells recognising SDC1 suggests that the treatment is safe, well-tolerable and has potential antitumour activity [232]. This evidence concerns the gene SDC1 and plasma cell myeloma.